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ABSTRAK
Narkotika lebih dikenal masyarakat karena masalah
penyalahgunaannya, padahal salah satu kelompok narkotika
yang digunakan dalam bidang medis adalah analgetika narkotika,
utamanya tablet morfin, yang merupakan obat esensial.
Penghitungan kebutuhan yang akurat untuk analgetika narkotika
sangat penting untuk memastikan ketersediaannya bagi
pelayanan kesehatan pasien. Saat ini data global menunjukkan
bahwa penggunaan morfin lebih terkonsentrasi di beberapa
negara di Eropa dan Amerika Utara saja, sedangkan di negara-
negara lain termasuk Indonesia, konsumsinya sangat minim.
Morfin bahkan tak tersedia di 70 negara dan teritori.
Penyebabnya bisa karena kurang akuratnya penghitungan
kebutuhan, kurang digunakan atau karena kebocoran distribusi.
Di lain pihak, ketidakakuratan penghitungan juga bisa
menyebabkan surplus persediaan yang bisa menyebabkan
kebocoran distribusi dan dapat mengarah ke penyalahgunaan.
Oleh karena itu, sangatlah penting untuk memilih metode
penghitungan kebutuhan morfin yang paling tepat, agar
kebutuhan medis terpenuhi secara optimal. Makalah ini
menyajikan sistem pengawasan internasional untuk penyediaan
narkotika bagi kebutuhan medis, dan langkah-langkah untuk
meningkatkan keakuratan penghitungan kebutuhan analgetika
narkotika, dengan tetap memperhatikan langkah-langkah
pengamanan distribusinya.
Kata Kunci: sistem pengawasan internasional, analgetika
narcotika, morfin, estimasi, metode kuantifikasi
ABSTRACT
Narcotics are popular to public more due to abuse, while people
are unaware that narcotic analgesics, particularly morphine
tablets, are essential medicines. To ensure the availability of
essential medicines, accurate estimation of the requirements
of narcotic analgesics is therefore of ultimate importance.
Currently, global data show that the use of morphine is more
concentrated in some countries in Europe and North America
alone, while in other countries, including Indonesia, the
consumption is very minimal. Morphine is not even available in
70 countries and territories. The reason could be due to
inaccurate estimation of the requirements, underuse, or due to
distortion in distribution. On the other hand, inaccurate
calculation can also result in surplus, leakage distribution, which
in turn leads to abuse. Therefore, it is important to choose the
most appropriate calculation method, which best meet the
medical requirement. This paper presents an international
monitoring system of narcotics for medical requirements, and
steps to improve the accuracy of the estimating the
requirements of narcotic analgesic, while considering the
control measures.
Keywords: international control system, narcotic analgesics,
morphine, estimates, quantification method
INTRODUCTION
The international drug control conventions were
elaborated in recognition of the fact that certain
substances while being of great benefit to mankind
were also liable to cause dependence syndrome.
Therefore the conventions established a control
system to serve a dual purpose, i.e., ensuring the
availability of controlled substances for medical and
scientific purposes while preventing the illicit
production of trafficking in and abuse of such
substances.1 An essential component of this
convention is a system under which countries are
requested to estimate the quantities of controlled
substances required for legitimate purposes and to
limit the use and trade of such substances within
the calculated estimates. If applied correctly, this
system should not hinder but should promote access
to adequate levels of controlled substances.
Unfortunately, many countries currently
encounter difficulties in calculating their legitimate
requirements for controlled substances, including
narcotic medicines, which can impede the availability
of such substances for medical and scientific
purposes.
The accurate estimation of requirements for
narcotic medicines is an essential step in ensuring
their adequate supply for medical purposes. On the
one hand, poor estimation of requirements can
contribute to many problems in the use of narcotic
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medicines in the health care system, notably
shortages, irrational prescribing, and distortion of
demand. On the other hand, poor estimation can
lead to surpluses, wastage and an increased risk of
diversion or abuses. Therefore, it is of utmost
importance to assist countries in quantifying the
estimates. This paper describes the system of
estimates and the recommended methods to use to
quantify the requirements of narcotic medicines for
medical purposes. It also provides an overview of
the major issues that need to be considered to
achieve accuracy in applying these methods.
The international drug control system
The international drug control system is based
on three international conventions: the Single
Convention on Narcotic Drugs, 1961, as amended
by the 1972 Protocol (1961 Convention)2, 1971
Convention on Psychotropic Substances (1971
Convention)3, and the 1988 United Nations
Convention against Illicit Trafficking in Narcotic Drugs
and Psychotropic Substances (1988 Convention).4
The 1961 and 1971 Conventions established control
measures over a defined number of narcotic drugs
and psychotropic substances, respectively, whereas
the 1988 Convention established control measures
on 23 precursor chemicals that are used in the illicit
manufacture of narcotic drugs and psychotropic
substances. By becoming parties to these
conventions, Governments have accepted the
obligation to translate the provisions of these treaties
into their national legislation and to implement them.
The International Narcotics Control Board (INCB)
is the body, established by the 1961 Convention,
responsible for monitoring the compliance of
Governments with the international drug control
treaties and for providing support to Governments in
this respect. The ability of INCB to monitor the
functioning of the international drug control
mechanisms established by the Conventions relies,
in part, on Governments to provide INCB with the
estimated quantities of internationally controlled
substances required for legitimate purposes in their
countries (known as estimates when referring to
narcotic drugs and precursor chemicals and as
assessments when referring to psychotropic
substances). The estimates and assessments,
which are examined and, if applicable, confirmed by
INCB, provide guidance for the quantities of controlled
substances that countries may manufacture, import
and export.
The accurate estimation of requirements for
narcotic medicines is an essential step in ensuring
their adequate supply for medical purposes. Poor
estimation of requirements can contribute to many
problems in the use of narcotic medicines in the
health care system, notably shortages, irrational
prescribing, distortion of demand and low cost-
effectiveness. On the other hand, poor estimation
can lead to surpluses, wastage and an increased
risk of diversion to illicit uses or abuses.
In principle, the process of estimating
requirements for controlled substances should be
based on effective methods and systematic
procedures to collect information about the use of
and the need for controlled substances.
Unfortunately, a number of factors make it difficult
for the competent authorities of many countries to
develop and use such methods and procedures. The
most common difficulties encountered include a lack
of technical knowledge, a general lack of resources,
a poorly developed health care infrastructure and the
absence of an institutional framework that prioritises
access to medicines for all segments of the
population. As a result, many Governments furnish
to INCB estimates of controlled substances that are
not sufficient to meet their requirements or fail to
furnish any estimates to INCB.
Problems of narcotic medicine use in the world
As described in the Article 20 of the 1961
Convention, countries must report the statistics of
controlled substances that have been used for
medical, research, and manufacturing purposes
during the previous year. Data are compiled by the
INCB and published in the Annual Statistics. The
Statistics for 2008 which was recently published in
February 2010 shows that the morphine consumption
level varies widely among countries (see Figure 1).5
The Figure shows that the consumption was very
high in some European and North American
countries, but very low in the rest of the world.
Seventy countries and territories even reported any
consumption. The highest consumption level was
reported by Austria, but it should be taken into
consideration that Austria uses morphine not only
as narcotic analgesics but also for the substitution
therapy to heroin addicts.
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Figure 1. The world morphine consumption in S-DDD,
year 2008. One S-DDD is defined as 100 mg daily dose
of morphine per day per 1 million
What does the Figure 1 shows? The bars show
the consumption level by country in S-DDD unit, and
countries are named in order following the level of
use. A wide variation can even be seen among
countries in the same region such as Latin America.
For example, Indonesia consumes 1 S-DDD during
the year of 2008. What does it mean? Was it
adequate to treat people? One S-DDD is a 100 mg
dose of morphine per day per one million people, as
recommended by the treatment guideline for palliative
care. One S-DDDs were 1 morphine doses per day
per one million people. A patient with terminal stage
of cancer may need 3-6 month morphine analgesic,
so roughly, 1 S-DDD is consumed by 2-4 patients. It
means that 1 S-DDD were consumed by 2-4 patients
per 1 million people. Did this amount meet the
requirement in the country? It should be taken into
consideration that there are several clinical condition
that need narcotic analgesic as well, such as
palliative care in HIV/AIDS, cancer, orthopedic
surgery, etc.
It has widely been known that there are
impediments to the use of narcotic medicines. In
addition to general health system impediments, such
as a weak infrastructure for delivering health services
and medicines of any kind, there is a subset of
impediments that are unique to narcotic medicines
given their abuse potential and legal classification
as controlled. With regard to opioid analgesics, the
INCB surveyed national drug control authorities in
1995,6 and again in 2007 regarding impediments to
the availability of opioid analgesics for medical use.
The results are summarized in Table 1. Although
conducted 12 years apart, it is striking how similar
the identified impediments were at each point in time.
The impediments are listed in descending order of
how many governments identified them, with those
listed first being the most frequently identified by
governments.
Table 1. Impediments to availability of opioid
analgesics, results of the INCB surveys
in 2007 and 1995
INCB survey 2007 INCB survey 1995 
 Concerns about 
addiction  
 Fear of addiction 
 Reluctance to 
prescribe or stock 
stemming from fear 
of legal 
consequences 
 Reluctance to 
prescribe or stock 
stemming from fear of 
legal consequences 
 Insufficient training 
of health-care 
Professionals 
 Lack of training of 
health care 
professionals 
 Laws or regulations 
that restrict the 
manufacture, 
distribution, 
prescribing or 
dispensing  
 Laws or regulations 
that restrict the 
manufacture, 
distribution, 
prescribing or 
dispensing 
 Administrative 
burden of regulatory 
requirements 
 Overly burdensome 
administrative 
requirements 
  Fear of diversion 
 Cost  Cost 
 Difficulties 
encountered in the 
distribution system 
 Inadequate health 
care resources, such 
as facilities and health 
care professionals 
 Insufficient import 
or manufacture 
 Insufficient amount of 
imported or 
manufactured in the 
country 
 Lack of national 
policy or guidelines  
 Lack of national policy 
or guidelines 
How the system of estimates works
The system of estimates of narcotic drugs was
established by the 1961 Convention (Articles 12 and
19). Estimates should be based on legitimate
medical and scientific requirements. The process of
calculating these estimates is useful for the
following. It allows the competent authorities to obtain
accurate and realistic information about the
quantities of controlled substances actually required
for medical purposes. It provides information that is
essential for authorities to ensure that sufficient
quantities of controlled substances are available to
the health care system. The estimate system informs
authorities about the levels required for legitimate
use so that they are able to limit their supply to
those quantities and to take appropriate measures
to prevent their diversion for illicit use.
The estimates furnished by Governments are
examined, confirmed if applicable, and published by
INCB to provide countries with guidance about
quantities of narcotic medicines by each country for
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licit purposes. By allowing the manufacture, import
and export in quantities that do not exceed the
estimates published by INCB, Governments can
reduce the risks of diversion of such substances for
illicit uses. The estimates of legitimate requirements
for narcotic drugs furnished by Governments also
allow INCB to promote a balance between their global
demand and their supply.
Responsibilities in ensuring the effectiveness of
the estimate system controlled substances
The national competent authorities (NCAs) are
responsible for calculating the estimates for
controlled substances to be furnished to INCB, and
developing a method to accurately determine the
legitimate requirements for medical purposes in their
countries. The NCAs are responsible for informing
operators (manufacturers, distributors and health
care providers) who provide information for preparing
the estimates about their legal obligation to provide
the relevant information. Operators should be
provided with the knowledge to carry out these
responsibilities, and the NCAs should organize the
collection of the relevant data from operators and
other sources. The NCAs are also responsible for
coordinating with other governmental bodies involved
in drug supply management and concerned with
public health, notably the ministry of health, to ensure
that conditions are met for the accurate quantification
of requirements for controlled substances.
The International Narcotics Control Board
(INCB), as mandated by the international drug control
conventions, assists Governments in complying with
their treaty obligations. The International Narcotics
Control Board (INCB) examines the estimates
furnished by Governments to help ensure that
controlled substances are available at levels that are
adequate to meet medical requirements and that
minimize the risk of their diversion. In the case of
narcotic drugs, INCB confirms the estimates furnished
by Governments, after obtaining additional
explanations of the intended usage of quantities
furnished if necessary. The International Narcotics
Control Board (INCB) publishes the estimates
provided by countries to share this public information
with all Governments.
There are no set limits on the estimates of
controlled substances that Governments should
furnish to INCB; it is only required that the quantities
furnished reflect the legitimate requirements.
Furthermore, INCB encourages increases in the
estimates when such increases respond to
increasing medical requirements and when
appropriate measures are in place to prevent
diversion. When a country fails to meet its treaty-
based obligation to furnish the estimates, these are
established by INCB to ensure that the country is
able to import controlled substances. Under such
circumstances, INCB requests the country in
question to revise the estimates in such that these
reflect more accurately the legitimate requirements.
Estimates for narcotic drugs
These estimates refers to the calculated
quantities of a specific narcotic medicines required
by a country for medical and scientific purposes for
the period of one year. Such estimates are
communicated on a yearly basis to INCB, which
reviews and confirms them, requesting additional
information from the government as needed, and may
confirm them. Article 19 of the 1961 Convention says
that Governments have the obligation to provide
estimates of their legitimate requirements of narcotic
drugs to INCB on an annual basis. If the annual
estimates furnished by Governments prove inadequate
to meet actual requirements in the course of the year
to which the estimates apply, Governments may
amend their annual estimates by furnishing
supplementary estimates to INCB (see Figure 2).
The INCB examines the annual estimates of drug
requirements furnished by Governments with a view
to ensure that narcotic medicines are available for
legitimate purposes only. After examining the
estimates provided by Governments and obtaining
satisfactory explanations as necessary, INCB
confirms the estimates and publishes them. The
annual estimates confirmed by INCB are valid for
one year. Article 21 of the 1961 Convention says
that countries should manufacture, import or utilize
narcotic drugs within the limits of the totals of
estimates published by INCB. These estimates also
serve as a guideline for exporting countries regarding
the limits of quantities of narcotic drugs which can
be imported by other countries.
 Figure 2. The estimate system for narcotic drugs
(simplified)
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When a country fails to submit to INCB its
estimates for requirements of narcotic drugs, these
estimates are established by INCB (see Article 12,
para. 3 of the 1961 Convention).  In doing so INCB
usually relies on previous estimates of the country
in question. However, INCB requests the concerned
Government to revise the estimates that have been
established, to reflect the most recent requirements
of its population and to inform INCB of those
revisions.
Considerations for the calculation of estimates
that accurately reflect medical requirements
One of the main purposes of calculating
estimates is to ensure that the quantities of
controlled substances made available to the health
system in a country accurately reflect the medical
requirements. To achieve this objective, the process
of quantifying these requirements should not be a
purely computational procedure carried out
independently, but rather, should be conducted within
the framework of the supply management system
for controlled substances. The following components
form the core of a controlled substance supply
management system:7,8 a). Selection: deciding which
controlled substances are required for treating the
health problems in the country, b). Quantification:
estimating how much of each controlled substance
is required to meet medical and scientific
requirements, c). Procurement: selecting suppliers,
placing and monitoring orders, checking delivery
quantities and quality, and paying suppliers,
d). Distribution: reception, storage, stock control,
transportation, and record keeping for monitoring and
control, e). Use: prescription, dispensing and use of
controlled substances and patients’ compliance with
prescriptions.
These components are interdependent and form
a cycle in which every step builds on the previous
one and leads to the next. Weaknesses in any step
of the cycle will have an impact on its effectiveness
and eventually on the adequate provision of the
controlled substances to the health system. Poor
quantification will obviously result in an incorrect
calculation of medical requirements, thereby limiting
the amount of controlled substances available to the
country. However, as discussed below, problems in
selection, procurement, distribution and irrational use
can also affect the accuracy of the quantification
process. This is especially important when
quantification is based on past consumption patterns,
as is the case for many of the countries that report
estimates to INCB.6
If the components of the supply management
system are managed by different agencies, then
coordination and information sharing among the
various agencies are essential to ensure that the
cycle is not interrupted. Each agency should be
aware of their responsibility and of how the
components of the system are supposed to work
together. Furthermore strategies should be
implemented to monitor the effectiveness of each
component of the cycle and of the entire system in
supplying the required quantities of controlled
substances.
In addition to these operational requirements,
the effectiveness of the supply management system
depends on a well functioning legal and policy
framework that is committed to ensuring the
availability and rational use of controlled substances
for medical purposes. The lack of such a framework
can hinder the functioning of the supply management
cycle and create impediments to the rational use of
narcotic medicines. Fundamental changes to the
legal and policy framework are then necessary to
eliminate these impediments to use.9
Methods for quantifying the requirements for
narcotic medicines
Three methods and their variants are commonly
used to quantify the requirements for controlled
substances: the consumption-based, service-based
and morbidity-based methods.10  The decision to
apply any one of the methods is determined by the
availability of the data needed for quantification, the
resources available and the structure of the controlled
substance supply system. However, it should be
taken into account that the morbidity-based method
will provide the closest figure to the medical need.
This method is the most recommended when the
morbidity pattern related is well documented and the
health care delivery is well-maintained.
This section outlines the optimal circumstances
under which each method can be applied to yield
accurate results and the main limitations of the
methods. In practice, all the conditions that contribute
to the accuracy of the methods may not be present.
This should however not preclude the application of
the methods since achieving accuracy in quantifying
requirements for controlled substances is an
incremental process. It depends not only on applying
the appropriate method but also on many factors
external to the quantification process. Efforts to
address these factors should be concurrent with a
gradual refinement of the estimates of requirements.
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Consumption-based method and its variants
The consumption-based method and its variants
are based on the use from recent years. If past use
of controlled substances is stable, future
requirements can be calculated by averaging the
amounts used in health facilities in recent years and
adding a margin for unforeseeable increases. In
variants of this method, calculations are based on
data obtained from manufacturers, importers and
wholesalers that distribute controlled substances to
peripheral health facilities.
Consumption-based method is appropriate in
the following situations, in the absence of
circumstances that might warrant a change (e.g.
emergency health situations), if the demand for health
services has reached a relatively steady state, when
the demands of the health care system are met by
a well-functioning supply management system that
ensures an uninterrupted supply of controlled
substances, when use of controlled substances is
rational, and when reliable data on past use can be
collected.
In using this method, it is important to be aware
that the consumption-based method and its variants
do not provide a detailed and systematic basis for
reviewing controlled substance use that could help
to improve rational use and the accuracy of the
quantification process. For example, if prescribing,
dispensing, and administering are poor and not
corrected, this method may perpetuate it. In the case
of calculations based on quantities requested by
trading companies for future sales, the calculated
amount may be influenced by limited marketing
possibilities or overly optimistic sales expectations,
and may therefore not reflect medical requirements.
Stock-outs over long periods of time and high loss
or wastage of controlled substances may reduce the
accuracy of the method. In addition, data collected
for the consumption-based method and its variants
may be incomplete for the following reasons: poor
stock management, inadequate record-keeping, and
inadequate reporting to the authorities responsible
for data collection.
Service-based method
The service-based method calculates controlled
substance requirements based on actual, current
levels of use of each controlled substance (for all
clinical indications) in a sample of standard facilities.
The data collected from the standard facilities can
then be extrapolated to calculate the requirements
of other similar facilities included in the quantification
process. This method targets the health services
available and takes into account their current
treatment levels, thereby reflecting the financial and
administrative constraints within the existing health
care system.
This method is appropriate in the following
situations, i.e., when prescribing, administering and
dispensing patterns in the standard facilities are
considered to be rational; for increased accuracy of
the method, strategies should be developed to
promote rational use in all facilities, when the pattern
of morbidity in the standard facilities is representative
of the pattern in the region included in the
quantification; if there are large differences in
morbidity patterns, other methods may be more
appropriate for calculating the requirements of those
non-standard facilities, and when detailed data on
patient morbidity or standard treatment guidelines
are not available.
Authorities should be aware that service based
methods may not take into account the medical
needs of patients that cannot be met due to cultural
or geographical constraints of the existing health
system. Any irrational patterns of use (prescribing,
administering, dispensing) in the standard facilities,
which are not corrected, may be perpetuated
throughout the health system as they are carried
over into the requirements for controlled substances
for other facilities included in the quantification
process. In addition, limitations of the health care
system (frequent stock-outs, irrational patterns of
use, poor record-keeping practices etc) may make
it difficult to select valid standard facilities. Service-
based methods may be difficult to apply for controlled
substances like benzodiazepines that are prescribed
not only in health care facilities but also by doctors
with variable prescribing patterns.
Morbidity-based method
The morbidity method calculates the
requirements for controlled substances based on an
assessment of the frequency of health problems
(morbidity) and on accepted treatment norms for the
health problems in question. Data on morbidity can
be obtained from epidemiological assessments at
the regional or national level. When complete data
on the population morbidity for a given health problem
is available, the method calculates the quantities of
controlled substance that would be necessary to
treat all the morbidity. However such data are rarely
available and may be difficult to collect. In such
situations, morbidity profiles of sample health
facilities can be used in the calculation and the
requirement scaled up to the regional or national level.
This method is appropriate in the following
situations, when data on past patterns of use of
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controlled substances are not available or are
unreliable, health services are new or rapidly changing
e.g. for starting an opioid substitution treatment
programme, accurate and complete data on
morbidity are available, standard treatment schedules
have been devised, to promote a change towards
more rational prescribing, as defined by  standard
treatment schedules, or when it is necessary to
counter-check the requirements calculated using
other methods.
Authorities should be aware that if standard
treatments schedules are not followed, the calculated
requirements for controlled substances will not match
their use. This method will accurately predict
requirements only for a limited number of health
problems for which complete morbidity data and
standard treatment schedules are available. Therefore
if a controlled substance is used to treat several
health problems, it may be necessary to use other
methods to estimate the quantities required to treat
those health problems to which the morbidity method
could not be applied due to data limitation. The
calculated requirement will be more accurate if
sample health facilities used in the calculation have
a morbidity profile that is representative of the regions
included in the quantification.
Stepping the quantification ladder
The quantification process serves to promote
the efficient procurement of controlled substances
and their rational use. To achieve these goals, regular
evaluation of the effectiveness of the quantification
process and of the accuracy of the calculated
requirements should be conducted. Continuous
monitoring of the quantification process is also
important to ensure its effectiveness.
Evaluation of the quantification process is useful
to assess the effectiveness with which the various
steps of the process (e.g. data collection) have been
carried out. Problems at each step should be
identified and corresponding solutions introduced. It
is also useful to determine whether modifications in
the method used are warranted. These modifications
should respond to changes in prevailing conditions
and available information and aim at achieving more
accurate quantification. Evaluation is necessary to
identify whether adjustments are necessary due to
new developments such as population growth and
new medicines, programmes and facilities.
The ultimate purpose of the quantification
process is to ensure the availability of controlled
substances for medical and scientific purposes.
However, several other factors and components of
the supply management system have an impact on
availability. These should be well understood and
accounted for before availability can be used as a
criteria to assess the predictive accuracy of the
quantification process.
The three methods, namely the consumption-
based, service-based and morbidity-based methods,
are commonly used to quantify the requirements for
controlled substances:. The decision to apply any
one of the methods is determined by the availability
of the data needed for quantification, the resources
available and the structure of the controlled
substance supply system. However, it should be
taken into account that the morbidity-based method
will provide the closest figure to the medical need.
This method is the most recommended when the
morbidity pattern related is well documented and the
health care delivery is well-maintained. Therefore,
countries should gradually step up from
consumption-based to morbidity-based method in
estimating their requirements of narcotic medicines
for medical purposes (Figure3).
 
Figure 3. The quantification ladder. To achieve ideal
level of narcotic medicine use, every country should
step up gradually to using the morbidity-based
method
CONCLUSION
The accurate estimation of requirements for
narcotic medicines is an essential step in ensuring
their adequate supply for medical purposes. Poor
estimation of requirements can contribute to many
problems in the use of narcotic medicines in the
health care system. The world consumption data
shows that morphine use is concentrated only in
small number of countries in the Europe and North
America, while in the rest of the world its consumption
level is inadequate to treat pain. Morphine is even
not accessible in 70 countries and territories.
Therefore, it is of utmost importance to in using the
most appropriate quantifying methods to estimate
narcotic medicines in order to meet their medical
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needs. To improve the access, countries should step
up their method of quantification, from consumption-
based to morbidity method. However, it should be in
a gradual process, taken into account the
improvement of measures in preventing the
medicines from distortion.
REFERENCES
1. International Narcotics Control Board. Training
material on compliance with the Single
Convention on Narcotic Drugs, 1961. Vienna,
2002. Available at http://www.incb.org
2. United Nations. Single Convention on Narcotic
Drugs, 1961. As amended by the 1972 Protocol
Amending the Single Convention on Narcotic
Drugs, 1961. Authors, New York, 1972.
3. United Nations. 1971 Convention on Psychotropic
Substances. Authors, New York, 1971.
4. United Nations. The 1988 United Nations
Convention against Illicit Trafficking in Narcotic
Drugs and Psychotropic Substances. Authors,
New York, 1988.
5. International Narcotics Control Board. Narcotic
Drugs. Estimated World Requirements for 2010,
Statistics for 2008. The United Nations, New
York, 2009.
6. International Narcotics Control Board. Report of
the International Narcotics Control Board for
1995: Availability of Opiates for Medical Needs.
The United Nations, New York, 1996. Available
at http://www.incb.org/pdf/e/ar/1995/suppl1en.
pdf
7. Managing drug supply. The selection,
procurement, distribution, and use of
pharmaceuticals, second edition. Kumarian
Press, Connecticut, 1997.
8. World Health Organization. Estimating drug
requirements: a practical manual. WHO Action
programme on essential drugs. Author, Geneva,
1988. (WHO/DAP/88.2)
9. World Health Organization. Promoting rational
use of medicines: core components. WHO
Policy Perspectives on Medicines, No. 005.
Author, Geneva, 2002. Available at http://apps.
who.int/medicinedocs/en/
10.  World Health Organization. Achieving Balance
in National Opioids Control Policy: Guidelines
for Assessment. Author, Geneva, 2000. Available
at http://apps.who.int/ medicinedocs/en/d/
Jwhozip39e/#Jwhozip39e
